Cancer News
OncoLink Cancer News - HealthDay

Strategies May Improve Outcomes for Rare Tumors

-- Rick Ansorge

Tuesday, June 23, 2009

TUESDAY, June 23 (HealthDay News) -- In women with placental-site trophoblastic tumors, stage-adapted management initiated within 48 months after the antecedent pregnancy is associated with improved overall survival and recurrence-free survival, according to a study published online June 23 in The Lancet.

Peter Schmid, M.D., of Imperial College London, and colleagues studied outcomes in 62 women who received surgery, chemotherapy, or both.

After 10 years, the researchers found that the rates of overall survival and recurrence-free survival were 70 and 73 percent, respectively. They found that 10-year overall survival was significantly higher among patients with stage I disease who were treated surgically than in patients with stages II to IV disease who received surgery and chemotherapy (90 percent versus 52 percent for stage II and 49 percent for stage III and IV). They also observed significantly poorer outcomes among women who initiated treatment more than 48 months after the antecedent pregnancy.

"For patients with localized disease, surgery is the preferred treatment because placental-site trophoblastic tumors tend to be more resistant to chemotherapy than are other forms of gestational trophoblastic disease," the authors conclude.

Full Text (subscription or payment may be required)

Specialties Cardiology
Diabetes & Endocrinology
Internal Medicine
Family Practice

Copyright © 2009 ScoutNews, LLC. All rights reserved.

I Wish You Knew

What every person should know when facing a cancer diagnosis

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More